News | January 30, 2013

Abbott Evolves to Focus on Diagnostics, with New High-Sensitivity Heart Attack Diagnostic Test

January 30, 2013 — January has been a month of change for Abbott, and a senior medical devices analyst from GlobalData asserts that the company’s latest cardiac diagnostics product represents the first step in a line of new diagnostic products that will act to deliver growth over the next few years.

Abbott announced in 2011 that it planned to separate into two companies, one in medical products including devices and diagnostics, and the other in research-based pharmaceuticals, and this separation was made official on Jan. 1, 2013. With the medical products company keeping the Abbott name, the research-based pharmaceutical company is now named AbbVie, and will feature billion dollar blockbuster drug Humira among its products.

With the dust only just beginning to settle from this split, Abbott exemplified its strong presence in the cardiac biomarker in vitro diagnostics space only a week later, by gaining CE marking for its Architect Stat High Sensitive Troponin-I Assay on Jan. 9, 2013. This will challenge products from other major players such as Roche and Siemens in the diagnostic troponin market in Europe.

Savade Solanki, Ph.D., GlobalData's senior analyst covering medical devices, describes the new product’s strengths: “Abbott has reported that this high-sensitivity troponin-I assay can provide reliable data to emergency physicians two to four hours after patient admission. This is a great improvement over early generation troponin assays, where multiple testing was often required, and patients sometimes had to wait over 12 hours to allow reliable detection of troponin levels. This test will enable caregivers to make critical patient management decisions earlier, and this should result in both health and economic benefits.”

“Early detection of myocardial infarction is imperative as it allows treatment to be initiated promptly, and therefore limits permanent damage to the heart muscle. The troponins are considered to be the gold-standard cardiac biomarkers for the diagnosis and risk management of myocardial infarctions and acute coronary syndrome. Following myocardial damage, both the specificity and rapid blood release of cardiac troponins facilitate higher sensitivity compared with historical markers such as creatine kinase-MB.”

Not only are cardiac biomarkers key diagnostic tools for emergency physicians and cardiologists, but also potential big business for developers — each year emergency departments in the United States and Europe evaluate chest pain in many millions of patients. GlobalData expects the continued trend of substitution away from first-generation troponin tests and towards high-sensitivity troponin assays by clinical laboratories across the major markets. However, due to the stringent U.S. Food and Drug Administration (FDA) regulations regarding the approval of medical devices, these tests will continue to be launched in Europe long before they are available in the United States.

This approval comes at a good time for Abbott: with the separation of its research-based pharmaceutical business and subsequent creation of AbbVie, Abbott will be relying heavily on its diagnostics businesses to deliver growth over the next few years. New products will of course drive growth, and in this regard, Abbott expects to launch multiple new molecular diagnostic products over the coming years. In particular, Abbott and other major in vitro diagnostic players will view the point-of-care (POC) diagnostics market as an area of significant potential. For example, on Jan. 23, 2013, Abbott reported global 16 percent growth of annual sales in its POC diagnostics business in 2012, and the company will expect further growth through international expansion.

“Though cardiac biomarker tests, including troponin-I, are already offered on commercially-available POC platforms, the limit of detection can be an issue for hospital laboratories and emergency rooms,” states Solanki. “This is particularly the case for acute conditions such as myocardial infarction, where there is now availability of low-cost high-sensitivity laboratory-based troponin testing. POC developers will need to continue to play catch-up with the laboratory-based assays and enhance the sensitivity of their tests in order to gain a real foothold.

“However, POC platforms have other advantages for hospitals. For example, Abbott’s i-STAT POC platform offers wireless information delivery that can be aligned with patients’ electronic medical records. Abbott, and other developers, will be looking to continue to facilitate the incorporation of their systems into hospital–patient work-flows, and once the sensitivity of tests such as troponin are also comparable, it may well be time to say farewell to the analyzer taking up a good portion of the laboratory bench.”

For more information:

Related Content

AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient
News | Blood Testing | September 04, 2018
Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD)...
More Sensitive Blood Test Diagnoses Heart Attacks Faster
News | Blood Testing | August 06, 2018
August 6, 2018 — A new test to assess a whether or not someone is having a...
Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Overlay Init